Gastrectomy for patients with gastric cancer and non-uremic renal failure

To investigate the safety and outcome of gastrectomy for patients with gastric cancer and non-uremic renal failure (NURF).

One hundred forty-seven patients who underwent gastrectomy for carcinoma were retrospectively divided into two groups: a group with Ccr values of > or = 50 mL/min (Group 1; n = 110), and one with Ccr values of > or = 20 to < 50 mL/min (Group 2; n = 37). Preoperative patient characteristics, intraoperative parameters (including operation time and blood loss), and postoperative management and complications were evaluated.

There were no statistically significant differences between the two groups in operation time (297.9 min vs 272.6 min, P = 0.137) or blood loss (435 mL vs 428 mL, P = 0.078). The differences in postoperative complications and hospital stay between the groups were not statistically significant. None of the patients in Group 2 required dialysis therapy, and no patients died due to gastrectomy or gastrectomy-related causes. The overall 4-year survival rates in Groups 1 and 2 were 86.6% and 81.8%, respectively (P = 0.48), and the corresponding 4-year disease-free survival rates for stage I, II, and III patients were 88.7% and 83.5%, respectively (P = 0.65).

Gastrectomy can be performed as safely in patients with NURF similar to patients with normal renal function.